BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
3/30/2026
Impact: 80
Healthcare
BTIG analyst Thomas Shrader has reiterated a Buy rating on Bright Minds Biosciences (NASDAQ: DRUG) and maintained a price target of $147 for the stock.
AI summary, not financial advice
Share: